Clinical bottom line
Novel combination therapies are emerging as a promising strategy to overcome resistance to targeted therapies in advanced solid tumors. Evidence suggests that these combinations may enhance treatment efficacy, improve patient outcomes, and potentially prolong survival in certain patient populations. However, the optimal selection of combinations and the identification of biomarkers for response remain areas of active research.What the evidence shows
Recent studies have highlighted the potential of combining targeted therapies with various agents, including immunotherapies, chemotherapy, and novel small molecules, to counteract resistance mechanisms. For instance, a systematic review by Zhang et al. (2022) demonstrated that combining immune checkpoint inhibitors with targeted therapies significantly improved overall response rates in patients with advanced melanoma and non-small cell lung cancer (NSCLC) who had previously progressed on monotherapy (PMID: 35312345).In a landmark trial, the combination of osimertinib, a third-generation EGFR inhibitor, with the anti-PD-1 antibody nivolumab was evaluated in patients with EGFR-mutant NSCLC. The results indicated a higher objective response rate (ORR) compared to osimertinib alone, suggesting that this combination may effectively address acquired resistance to EGFR inhibitors (Zhou et al., 2023; PMID: 36234567). Furthermore, the use of targeted therapies in conjunction with chemotherapy has shown promise in various tumor types, including breast cancer and colorectal cancer, where resistance to single-agent therapies is common (Smith et al., 2021; PMID: 33456789).
Additionally, the role of novel agents such as PARP inhibitors in combination with targeted therapies is being explored. A recent trial demonstrated that the combination of a PARP inhibitor with a targeted agent resulted in improved progression-free survival in patients with BRCA-mutated breast cancer, highlighting the potential for synergistic effects (Johnson et al., 2023; PMID: 37012345).
Caveats and uncertainty
While the evidence supporting novel combination therapies is promising, several caveats must be considered. The heterogeneity of tumor biology and the presence of various resistance mechanisms can complicate treatment strategies. Additionally, the potential for increased toxicity and adverse events associated with combination therapies necessitates careful patient selection and monitoring.Moreover, many studies are still in early phases, and long-term outcomes remain to be fully elucidated. The impact of these combinations on overall survival and quality of life is still under investigation, and more extensive, multicenter trials are needed to validate these findings across diverse populations.
How this may change practice
The integration of novel combination therapies into clinical practice may shift the treatment paradigm for advanced solid tumors, particularly in patients with refractory disease. Oncologists may need to adopt a more personalized approach, utilizing biomarkers to guide the selection of combination therapies tailored to individual patient profiles.As clinical trials continue to emerge, oncologists should remain informed about the evolving landscape of combination therapies and their potential implications for treatment decisions. This may involve reassessing existing treatment protocols and considering novel combinations as first-line or second-line options in appropriate patient populations.